Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PDL BioPharma | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

PDL BioPharma

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PDL BioPharma, Inc. has named Andrew Guggenhime senior vice president and chief financial officer. Mr. Guggenhime will join the company’s senior management team reporting directly to chief executive officer Mark McDade, and will be responsible for all financial and information technology operations of the company.

Mr. Guggenhime joins the company from Neoforma, Inc. where he had been chief financial officer since October 2000. In this role, he was responsible for the accounting, finance, financial planning and analysis, investor relations, legal and facilities departments. He was previously vice president of corporate development, managing Neoforma’s corporate development, business development, international and strategic efforts. Prior to joining Neoforma, he was a vice president in the Healthcare Investment Banking group of Merrill Lynch & Co., where he specialized in working with healthcare services firms and healthcare Internet companies on a variety of transactions, including mergers and acquisitions, initial public offerings, add-on equity offerings and debt offerings. Previously, he worked at Wells Fargo & Company in a number of capacities.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics